Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- Bosulif (bosutinib)
- strontium-89 chloride
Interactions between your drugs
strontium-89 chloride bosutinib
Applies to: strontium-89 chloride, Bosulif (bosutinib)
ADJUST DOSING INTERVAL: The concomitant use of bone marrow depressants or cytotoxic agents with strontium-89 chloride may result in additive myelosuppression. Bone marrow toxicity is expected following the administration of strontium-89 chloride alone, especially with regards to white blood cells (WBCs) and platelets. The nadir of platelet depression for most patients is about 4 to 16 weeks after a strontium-89 chloride injection. Recovery can be slow and may not be complete.
MANAGEMENT: Concomitant use of strontium-89 chloride and a bone marrow suppressant or cytotoxic agent is not generally recommended. Some authorities advise separating strontium-89 chloride administration from that of a cytotoxic agent by an interval of at least 12 weeks, provided that the patient's hematological parameters are stable and within the normal range. The product labeling for the concomitant myelosuppressive/cytotoxic medication should be consulted for more specific recommendations. Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms.
References (3)
- (2014) "Product Information. Metastron (strontium (89Sr) chloride)." GE Healthcare Australia Pty Ltd
- GE Healthcare Canada Inc. (2023) Product monograph metastron strontium [89Sr] chloride https://pdf.hres.ca/dpd_pm/00020852.PDF
- Isotherapeutics Group LLC (2023) Strontium chloride SR-89- strontium chloride sr-89 injection https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c89bcf16-399d-48e0-a4e3-849261aaa310&type=display
Drug and food interactions
bosutinib food
Applies to: Bosulif (bosutinib)
ADJUST DOSING INTERVAL: Food enhances the oral bioavailability of bosutinib. When given with a high-fat meal, bosutinib peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 1.8- and 1.7-fold, respectively.
GENERALLY AVOID: Coadministration with grapefruit juice is likely to increase the plasma concentrations of bosutinib, which is primarily metabolized by CYP450 3A4. However, the interaction has not been studied. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.
MANAGEMENT: Bosutinib should be administered with a meal. The consumption of grapefruit, grapefruit juice, and supplements that contain grapefruit extract should be avoided.
References (1)
- (2012) "Product Information. Bosulif (bosutinib)." Pfizer U.S. Pharmaceuticals Group
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Hydrea
Hydrea is used for chronic myelogenous leukemia, head and neck cancer
Sprycel
Sprycel is used to treat chronic myeloid leukemia and acute lymphoblastic leukemia. Learn about ...
Ubrelvy
Ubrelvy (ubrogepant) tablets are used for the acute treatment of migraine. Includes Ubrelvy side ...
Gleevec
Gleevec is targeted cancer therapy for specific types of leukemia (blood cancer), bone marrow ...
Cytoxan
Cytoxan is used for acute lymphocytic leukemia, acute nonlymphocytic leukemia, breast cancer ...
Tasigna
Tasigna (nilotinib) is used to treat Philadelphia chromosome positive chronic myeloid leukemia ...
Ponatinib
Ponatinib is used to treat chronic myeloid leukemia and Philadelphia chromosome positive acute ...
Dasatinib
Dasatinib is used to treat Philadelphia chromosome-positive chronic myelogenous leukemia (CML) ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.